Last updated: February 16, 2026
What Is the Current Market Status of NDC 42192-0615?
NDC 42192-0615 corresponds to Voxzogo (vosoritide), developed by BioMarin Pharmaceuticals. Approved by the FDA in May 2021 specifically for achondroplasia in pediatric patients aged 5 years and older.
The market for vosoritide is emerging with limited direct competition. Its primary addressable market includes children with achondroplasia, estimated globally at approximately 250,000 individuals.
How Does the Drug Position in the Market?
Voxzogo’s approval addresses a niche segment with no approved pharmacologic therapies for growth deficiency in achondroplasia. The drug's initial launch target is primarily the United States, with plans for expansion to Europe and other regions.
BioMarin projects peak sales between $800 million and $1 billion annually within 7-10 years post-launch, based on market penetration assumptions. Factors influencing market penetration include:
- Reimbursement environment
- Physician adoption rates
- Patient adherence
- Competitive landscape
What Are the Regulatory and Pricing Policies Affecting Voxzogo?
Regulatory Policies
- FDA Approval: May 2021, based on a Phase 3 trial demonstrating increased annualized growth velocity (up to 2.0 cm/year in some patients).
- European Medicines Agency (EMA): Not yet approved, targeted for submission in 2023.
- Pricing regulations: Vary between US and Europe; US pricing set through negotiations with payers.
Pricing Strategies
In the US, BioMarin has set a list price of approximately $123,000 per year. The pricing reflects:
- Cost of manufacturing
- R&D recovery
- Market exclusivity
- Value-based pricing, considering the impact on disease progression
Coverage by insurers is expected to be favorable due to regulatory approval and clinical efficacy evidence, but some patients may face access barriers due to high out-of-pocket costs.
What Are the Price Projections and Revenue Expectations?
Assuming market penetration of 10-15% of eligible patients initially, with growth over time, revenues are projected as follows:
| Year |
Estimated Revenue |
Justification |
| Year 1 |
$50 million to $100 million |
Limited initial adoption, primarily in US. |
| Year 3 |
$200 million to $400 million |
Increased physician familiarity and expanded payer coverage. |
| Year 5 |
$500 million to $700 million |
Broader European entry and higher market penetration. |
| Year 10 |
Up to $1 billion |
Peak sales with expanded indications and global reach. |
Price stabilization is contingent on payer negotiations and competitive pressures. Price erosion might occur over time, especially if generic or biosimilar options emerge or if biosimilars gain approval.
What Is the Competitive Landscape?
Currently, no direct pharmacologic treatments are approved for achondroplasia-specific growth. Off-label treatments such as growth hormone therapy have limited efficacy and are not approved for this indication.
Emerging pipeline products include:
- recifercept, a fibroblast growth factor receptor 3 (FGFR3) inhibitor in clinical development
- Other biologics targeting the FGFR3 pathway
Market exclusivity granted by FDA's orphan drug designation extends until 2030, providing a temporary monopoly.
What Are the Key Market Risks and Opportunities?
Market Risks
- Reimbursement challenges: Physician and payer acceptance depends on demonstrated long-term benefits.
- Entry of competitors: Biosimilars or drugs with improved efficacy could depress prices.
- Limited indication scope: Approved solely for children aged 5 and above limits market size.
Market Opportunities
- Expanding indications: Use in younger children or adult patients.
- Global expansion: Entering non-European markets with high achondroplasia prevalence.
- Combination therapies: Potential future treatments combining vosoritide with other agents.
Closing Summary
Voxzogo remains in the early stages of commercial adoption, with a strong initial valuation based on unmet clinical need and regulatory approval. Pricing remains aligned with therapeutic value and market expectations. As the drug gains broader acceptance and enters additional markets, revenue projections are expected to increase significantly, albeit with risks related to reimbursement and competitive developments.
Key Takeaways
- The US launch price is ~$123,000 annually; global pricing strategies are region-dependent.
- Peak global sales could reach up to $1 billion by 2033, depending on market penetration and approval timing.
- No direct competitors currently market approved therapies; pipeline drugs are under development.
- Reimbursement strategy and regulatory expansion efforts are critical to revenue growth.
- Risks include payer resistance, potential biosimilar entry, and limited market size due to age restrictions.
FAQs
1. What factors influence the pricing of vosoritide?
Pricing is influenced primarily by clinical efficacy, manufacturing costs, market exclusivity, and negotiations with payers. Regulatory approval and perceived value also play significant roles.
2. How does the market size for vosoritide compare globally?
The global childhood achondroplasia population is approximately 250,000 individuals. The US accounts for roughly 30%, with Europe and other markets representing additional segments.
3. Are there any approved alternatives to vosoritide?
No drugs are approved specifically for achondroplasia's growth deficiency. Growth hormone therapies are off-label and limited in efficacy.
4. What is the potential for biosimilar competition?
Biosimilars may enter after patent expiry around 2030, which could impact pricing and market share.
5. What is the likelihood of expanding the indication for vosoritide?
Expansions to include younger children or adult patients are under consideration, contingent on ongoing clinical trial results and regulatory review.
References
[1] BioMarin Pharmaceuticals. "Voxzogo (vosoritide) Prescribing Info," 2021.
[2] FDA. "Voxzogo (vosoritide) Approval Press Release," May 2021.
[3] EvaluatePharma. "2019 World Preview: Outlook to 2024."
[4] IQVIA, "Healthcare Market Reports," 2022.
